SOPHiA GENETICS (NASDAQ:SOPH) President Sells $13,484.24 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) President Ross Muken sold 2,786 shares of the firm’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $4.84, for a total transaction of $13,484.24. Following the completion of the transaction, the president directly owned 695,311 shares of the company’s stock, valued at $3,365,305.24. This represents a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,804.88.
• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $5,666.57.

SOPHiA GENETICS Stock Performance

SOPH stock opened at $4.70 on Monday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. The company has a fifty day moving average price of $4.75 and a two-hundred day moving average price of $4.70. SOPHiA GENETICS SA has a one year low of $2.58 and a one year high of $5.70. The stock has a market cap of $321.90 million, a price-to-earnings ratio of -9.22 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. Equities analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Guggenheim lifted their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research reaffirmed a “buy” rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors have recently modified their holdings of the business. Alta Wealth Advisors LLC bought a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $6,708,000. Polen Capital Management LLC bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $102,000. Susquehanna International Group LLP bought a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $88,000. XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $55,000. Finally, Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $54,000. Institutional investors own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.